Skip to content
Vinony
English
EnglishBahasa IndonesiaDeutschEspañolFrançaisItalianoNederlandsPolskiTiếng ViệtРусскийالعربية中文日本語
zileuton

Structure via PubChem · Public domain (PubChem)

EntityQ202998· pop 17· linked from 175 articles

zileuton

Sign in to save

Also known as A-64077, ZYFLO®, Leutrol, N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea, N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea, (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea, N-[1-(Benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea

thumb|300px|Abbott Laboratories stock bottle of Zyflo (zileuton) 600 mg tablets (manufactured 1997). Also shown are Zyflo tablets, with one tab broken. Tablets are branded with the Abbott "a" logo and "ZL". Zileuton (trade name Zyflo) is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, used for the maintenance treatment of asthma. Zileuton was introduced in 1996 by Abbott Laboratories and is now marketed in two formulations by Cornerstone Therapeutics Inc. under the brand names Zyflo and Zyflo CR. The original immediate-r

Chemical data

Formula
C11H12N2O2S
Molecular weight
236.29 g/mol
IUPAC name
1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
SMILES
CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O
InChIKey
MWLSOWXNZPKENC-UHFFFAOYSA-N
XLogP
1.6
Polar surface area
94.8 Ų
H-bond donors
2
H-bond acceptors
3
Formal charge
0

via PubChem

Drug data · ChEMBL

Max clinical phase
Approved
Molecule type
Small molecule
First approval
1996
Admin. routes
oral
Indications
nicotine dependence, idiopathic pulmonary fibrosis, chronic myelogenous leukemia, chronic obstructive pulmonary disease

via ChEMBL · EBI

Research

826 papers

via PubMed

Wikidata facts

Subclass of
chemical compound
Mass
236.061949
Has use
medication
Show 7 more facts
chemical formula
C₁₁H₁₂N₂O₂S
canonical SMILES
CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O
medical condition treated
asthma
World Health Organisation international non-proprietary name
zileuton
subject has role
carcinogen
Commons category
Zileuton
safety classification and labelling
Regulation (EC) No. 1272/2008
Sources (9)

via Wikidata · CC0

~7 min read

Encyclopedic overview

15 sections
Contents
  • Pharmacotherapy
  • Indications and dosing
  • Contraindications and warnings
  • Chemistry
  • Pharmacokinetics
  • Adverse effects
  • Interactions
  • Drug interactions
  • Other interactions
  • Overdose/toxicology
  • Symptoms
  • Treatment
  • See also
  • References
  • External links

thumb|300px|Abbott Laboratories stock bottle of Zyflo (zileuton) 600 mg tablets (manufactured 1997). Also shown are Zyflo tablets, with one tab broken. Tablets are branded with the Abbott "a" logo and "ZL". Zileuton (trade name Zyflo) is an orally active inhibitor of 5-lipoxygenase, and thus inhibits leukotrienes (LTB4, LTC4, LTD4, and LTE4) formation, used for the maintenance treatment of asthma. Zileuton was introduced in 1996 by Abbott Laboratories and is now marketed in two formulations by Cornerstone Therapeutics Inc. under the brand names Zyflo and Zyflo CR. The original immediate-release formulation, Zyflo, is taken four times per day. The extended-release formulation, Zyflo CR, is taken twice daily.

Although the 600 mg immediate release tablet (Zyflo) and extended release formulation of zileuton are still available (Zyflo CR), the 300 mg immediate release tablet was withdrawn from the U.S. market on February 12, 2008.

Excerpted from Wikipedia’s “zileuton” article, available under the CC BY-SA 4.0 licence.

Gallery (3)

Available in 16 languages

via Wikidata sitelinks · CC0